{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:31:22Z","timestamp":1786735882756,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pathol Microbiol"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/ijpm.ijpm_69_19","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T03:27:50Z","timestamp":1571023670000},"page":"566","source":"Crossref","is-referenced-by-count":0,"title":["Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma"],"prefix":"10.4103","volume":"62","author":[{"given":"Jianping","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0377-4929.269079-1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/0377-4929.269079-2","unstructured":"Travis WD, Brambilla EBP, Marx A, Nichol-Son A. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: WHO; 2015."},{"key":"key-10.4103\/0377-4929.269079-3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/icvts\/ivu267","article-title":"Palliative treatment for symptomatic malignant pericardial effusion","author":"Jama","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"key-10.4103\/0377-4929.269079-4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1477-7819-12-249","article-title":"Prognostic factors affecting survival of patients with cancer-related pericardial effusion managed by surgery","author":"Jeon","year":"2014","journal-title":"World J Surg Oncol"},{"key":"key-10.4103\/0377-4929.269079-5","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1378\/chest.125.4.1328","article-title":"Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy","author":"Cullinane","year":"2004","journal-title":"Chest"},{"key":"key-10.4103\/0377-4929.269079-6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4143\/crt.2010.42.4.210","article-title":"Clinical Characteristics of Malignant Pericardial Effusion Associated with Recurrence and Survival","author":"Kim","year":"2010","journal-title":"Cancer Res Treat"},{"key":"key-10.4103\/0377-4929.269079-7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2217\/fon.15.349","article-title":"Concepts in cardio-oncology: Definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity","author":"Wickramasinghe","year":"2016","journal-title":"Future Oncol"},{"key":"key-10.4103\/0377-4929.269079-8","first-page":"1169","article-title":"Molecular profiling of malignant pleural effusion in metastatic non-small-cell lung carcinoma.The effect of preanalytical factors","author":"Carter","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"key-10.4103\/0377-4929.269079-9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cyt.12322","article-title":"Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer","author":"Zhong","year":"2016","journal-title":"Cytopathology"},{"key":"key-10.4103\/0377-4929.269079-10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/cncy.21532","article-title":"Cytopathology of pulmonary adenocarcinoma with a single histological pattern using the proposed international association for the study of lung cancer\/American thoracic society\/European respiratory society (IASLC\/ATS\/ERS) classification","author":"Rodriguez","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"key-10.4103\/0377-4929.269079-11","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.269079-12","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0377-4929.269079-13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists\/ International association for the Study of lung cancer\/Association for molecular pathology clinical practice guideline update","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0377-4929.269079-14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5858\/arpa.2013-0759-OA","article-title":"Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura","author":"Raparia","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"key-10.4103\/0377-4929.269079-15","first-page":"279","article-title":"Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification","author":"Cil","year":"2017","journal-title":"J BUON"},{"key":"key-10.4103\/0377-4929.269079-16","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","author":"Sos","year":"2009","journal-title":"Cancer Res"},{"key":"key-10.4103\/0377-4929.269079-17","first-page":"75","article-title":"Malignant cardiac tamponade from non-small cell lung cancer: Case series from the Era of molecular targeted therapy","author":"Bob","year":"2015","journal-title":"J Clin Med"},{"key":"key-10.4103\/0377-4929.269079-18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.6004\/jnccn.2018.0046","article-title":"Targeted therapy for patients with metastatic non\u2013small cell lung cancer","author":"Reckamp","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"key-10.4103\/0377-4929.269079-19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0000000000000203","article-title":"Multiplexed molecular profiling of lung cancer using pleural effusion","author":"Akamatsu","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key-10.4103\/0377-4929.269079-20","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.21037\/jtd.2018.04.125","article-title":"Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens","author":"Liu","year":"2018","journal-title":"J Thorac Dis"},{"key":"key-10.4103\/0377-4929.269079-21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/modpathol.2009.154","article-title":"Clinicopathological predictors of EGFR\/KRAS mutational status in primary lung adenocarcinomas","author":"Dacic","year":"2010","journal-title":"Mod Pathol"},{"key":"key-10.4103\/0377-4929.269079-22","first-page":"5111","article-title":"Cytological features of lung adenocarcinoma with micropapillary pattern in the pleural or pericardial effusion: Analysis of 5 cases","author":"Ishida","year":"2014","journal-title":"Int J Clin Exp Patho"},{"key":"key-10.4103\/0377-4929.269079-23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000477148","article-title":"Molecular alterations in patients with pulmonary adenocarcinoma presenting with malignant pleural effusion at the first diagnosis","author":"Rodriguez","year":"2017","journal-title":"Acta Cytol"},{"key":"key-10.4103\/0377-4929.269079-24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdn679","article-title":"Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer","author":"Gow","year":"2009","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0377-4929.269079-25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s13402-012-0078-4","article-title":"EGFR and KRAS mutations in lung carcinomas in the Dutch population: Increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma","author":"Smits","year":"2012","journal-title":"Cell Oncol"},{"key":"key-10.4103\/0377-4929.269079-26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/cncy.21288","article-title":"Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma","author":"Cai","year":"2013","journal-title":"Cancer Cytopathol"},{"key":"key-10.4103\/0377-4929.269079-27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant-selective EGFR kinase inhibitors against EGFR T790M","author":"Zhou","year":"2009","journal-title":"Nature"},{"key":"key-10.4103\/0377-4929.269079-28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12032-013-0645-1","article-title":"Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients","author":"Song","year":"2013","journal-title":"Med Oncol"},{"key":"key-10.4103\/0377-4929.269079-29","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1136\/jcp.2010.081166","article-title":"Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma","author":"Jokoji","year":"2010","journal-title":"J Clin Pathol"},{"key":"key-10.4103\/0377-4929.269079-30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/fon.09.164","article-title":"Clinical implications of met gene copy number in lung cancer","author":"Toschi","year":"2010","journal-title":"Future Oncol"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:34:39Z","timestamp":1786732479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJPM.IJPM_69_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"alternative-id":["269079"],"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_69_19","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}